1. Home
  2. FENG vs NCEL Comparison

FENG vs NCEL Comparison

Compare FENG & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phoenix New Media Limited

FENG

Phoenix New Media Limited

HOLD

Current Price

$1.49

Market Cap

18.0M

Sector

Industrials

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

HOLD

Current Price

$3.96

Market Cap

22.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FENG
NCEL
Founded
1998
2008
Country
China
Switzerland
Employees
N/A
4
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.0M
22.0M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
FENG
NCEL
Price
$1.49
$3.96
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.3K
33.4K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$1.83
52 Week High
$3.65
$5.12

Technical Indicators

Market Signals
Indicator
FENG
NCEL
Relative Strength Index (RSI) 40.33 59.35
Support Level N/A $2.73
Resistance Level $1.80 $4.67
Average True Range (ATR) 0.04 0.42
MACD -0.00 -0.01
Stochastic Oscillator 9.37 48.59

Price Performance

Historical Comparison
FENG
NCEL

About FENG Phoenix New Media Limited

Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives all of its revenue from PRC.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: